Cell Reports (Jun 2024)
Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption
- Thembi Mdluli,
- Bonnie M. Slike,
- Daniel J. Curtis,
- Zhanna Shubin,
- Ursula Tran,
- Yifan Li,
- Vincent Dussupt,
- Letzibeth Mendez-Rivera,
- Suteeraporn Pinyakorn,
- Daniel J. Stieh,
- Frank L. Tomaka,
- Hanneke Schuitemaker,
- Maria G. Pau,
- Donn J. Colby,
- Eugène Kroon,
- Carlo Sacdalan,
- Mark de Souza,
- Nittaya Phanupak,
- Denise C. Hsu,
- Jintanat Ananworanich,
- Julie A. Ake,
- Lydie Trautmann,
- Sandhya Vasan,
- Merlin L. Robb,
- Shelly J. Krebs,
- Dominic Paquin-Proulx,
- Morgane Rolland
Affiliations
- Thembi Mdluli
- US Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA
- Bonnie M. Slike
- US Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA
- Daniel J. Curtis
- US Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA
- Zhanna Shubin
- US Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA
- Ursula Tran
- US Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA
- Yifan Li
- US Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA
- Vincent Dussupt
- US Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA
- Letzibeth Mendez-Rivera
- US Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA
- Suteeraporn Pinyakorn
- US Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA
- Daniel J. Stieh
- Janssen Vaccines & Prevention BV, 2333 Leiden CN, the Netherlands
- Frank L. Tomaka
- Janssen R & D US, Titusville, NJ, USA
- Hanneke Schuitemaker
- Janssen Vaccines & Prevention BV, 2333 Leiden CN, the Netherlands
- Maria G. Pau
- Janssen Vaccines & Prevention BV, 2333 Leiden CN, the Netherlands
- Donn J. Colby
- US Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA; SEARCH, Institute of HIV Research and Innovation, Bangkok 10330, Thailand
- Eugène Kroon
- SEARCH, Institute of HIV Research and Innovation, Bangkok 10330, Thailand
- Carlo Sacdalan
- SEARCH, Institute of HIV Research and Innovation, Bangkok 10330, Thailand
- Mark de Souza
- SEARCH, Institute of HIV Research and Innovation, Bangkok 10330, Thailand
- Nittaya Phanupak
- SEARCH, Institute of HIV Research and Innovation, Bangkok 10330, Thailand
- Denise C. Hsu
- US Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA
- Jintanat Ananworanich
- US Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA
- Julie A. Ake
- US Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
- Lydie Trautmann
- US Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA
- Sandhya Vasan
- US Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA
- Merlin L. Robb
- US Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA
- Shelly J. Krebs
- US Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
- Dominic Paquin-Proulx
- US Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA
- Morgane Rolland
- US Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA; Corresponding author
- Journal volume & issue
-
Vol. 43,
no. 6
p. 114344
Abstract
Summary: A heterologous Ad26/MVA vaccine was given prior to an analytic treatment interruption (ATI) in people living with HIV-1 (mainly CRF01_AE) who initiated antiretroviral treatment (ART) during acute HIV-1. We investigate the impact of Ad26/MVA vaccination on antibody (Ab)-mediated immune responses and their effect on time to viral rebound. The vaccine mainly triggers vaccine-matched binding Abs while, upon viral rebound post ATI, infection-specific CRF01_AE binding Abs increase in all participants. Binding Abs are not associated with time to viral rebound. The Ad26/MVA mosaic vaccine profile consists of correlated non-CRF01_AE binding Ab and Fc effector features, with strong Ab-dependent cellular phagocytosis (ADCP) responses. CRF01_AE-specific ADCP responses (measured either prior to or post ATI) are significantly higher in individuals with delayed viral rebound. Our results suggest that vaccines eliciting cross-reactive responses with circulating viruses in a target population could be beneficial and that ADCP responses may play a role in viral control post treatment interruption.
